The US biotech aims to bring its antibody-based therapies to human trials later in the year and to develop new candidate therapies using the same platform. Hinge Bio is based in Burlingame, California ...

The oversubscribed Series C financing round will support the clinical development of in vivo CAR-T cells for oncology and autoimmune diseases. The U.S. biotech company Umoja Biopharma announced this ...